D.A. Davidson & Co’s Invesco Biotechnology & Genome ETF PBE Stock Holding History

D.A. Davidson & Co’s Portfolio PBE Stock Details PBE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q3	–	Sell	-100	Closed	-$4K	–	1725
2017 Q2	$4K	Sell	100 -181	-64%	-$7.81K	﹤0.01%	2234
2017 Q1	$11K	Hold	281	–	–	﹤0.01%	2002
2016 Q4	$10K	Hold	281	–	–	﹤0.01%	2119
2016 Q3	$11K	Hold	281	–	–	﹤0.01%	2025
2016 Q2	$10K	Sell	281 -876	-76%	-$34.4K	﹤0.01%	1959
2016 Q1	$43K	Buy	1,157 +876	+312%	+$34K	﹤0.01%	1451
2015 Q4	$14K	Hold	281	–	–	﹤0.01%	1808
2015 Q3	$12K	Hold	281	–	–	﹤0.01%	1821
2015 Q2	$16K	Hold	281	–	–	﹤0.01%	1755
2015 Q1	$15K	Hold	281	–	–	﹤0.01%	1721
2014 Q4	$14K	Hold	281	–	–	﹤0.01%	1757
2014 Q3	$12K	Hold	281	–	–	﹤0.01%	1791
2014 Q2	$12K	Hold	281	–	–	﹤0.01%	1763
2014 Q1	$11K	Hold	281	–	–	﹤0.01%	1782
2013 Q4	$10K	Hold	281	–	–	﹤0.01%	1720
2013 Q3	$9K	Hold	281	–	–	﹤0.01%	1488
2013 Q2	$8K	Buy	+281	New	+$7.99K	﹤0.01%	1462

Other funds holding PBE

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

LTFS

Ladenburg Thalmann Financial Services Miami, Florida $15.9B AUM 25.16% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

CAS

Cue Advisory Services Phoenix, Arizona $167M AUM 18.62% 1-Year Est. Return

RJFSA

Raymond James Financial Services Advisors St. Petersburg, Florida $75.1B AUM 31.89% 1-Year Est. Return

D.A. Davidson & Co's PBE Position: Q3 2017 in Review

D.A. Davidson & Co sold out of Invesco Biotechnology & Genome ETF (PBE) in Q3 2017, closing a stake of 100 shares — an estimated $4K sold.

D.A. Davidson & Co first reported a position in PBE in Q2 2013 and held it in 17 quarters. The position peaked at $43K in Q1 2016. 60 funds tracked by Wall St. Rank hold PBE as of Q3 2017.

D.A. Davidson & Co reported no remaining Invesco Biotechnology & Genome ETF position as of Q3 2017 after selling out during the quarter.
D.A. Davidson & Co sold 100 Invesco Biotechnology & Genome ETF shares in Q3 2017, an estimated $4K.
D.A. Davidson & Co first reported a position in Invesco Biotechnology & Genome ETF in Q2 2013 and held it in 17 quarters.
D.A. Davidson & Co's Invesco Biotechnology & Genome ETF position peaked at $43K in Q1 2016.
60 funds tracked by Wall St. Rank held Invesco Biotechnology & Genome ETF as of Q3 2017.

Based on D.A. Davidson & Co's 13F filing for Q3 2017, filed 8 Nov 2017.